Medite Cancer Diagnostics (Medite Cancer Diagnostics) FCF Margin % : -34.75% (As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medite Cancer Diagnostics's Free Cash Flow for the three months ended in Sep. 2018 was $-0.83 Mil. Medite Cancer Diagnostics's Revenue for the three months ended in Sep. 2018 was $2.39 Mil. Therefore, Medite Cancer Diagnostics's FCF Margin % for the quarter that ended in Sep. 2018 was -34.75%.

As of today, Medite Cancer Diagnostics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Medite Cancer Diagnostics's FCF Margin % or its related term are showing as below:

MDIT' s FCF Margin % Range Over the Past 10 Years
Min: -65.13 Med: 0 Max: 0
Current: -65.13

MDIT's FCF Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -7.14 vs MDIT: -65.13

Medite Cancer Diagnostics FCF Margin % Historical Data

The historical data trend for Medite Cancer Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics FCF Margin % Chart

Medite Cancer Diagnostics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

FCF Margin %

Get a 7-Day Free Trial

-5.01

-12.33

-6.03

-13.05

-54.35

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
FCF Margin %	Get a 7-Day Free Trial															-28.41	-92.14	-109.17	-44.70	-34.75

Competitive Comparison of Medite Cancer Diagnostics's FCF Margin %

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medite Cancer Diagnostics's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's FCF Margin % falls into.

Medite Cancer Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Medite Cancer Diagnostics's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-3.703	/	6.813
	=	-54.35 %

Medite Cancer Diagnostics's FCF Margin for the quarter that ended in Sep. 2018 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2018 )	/	Revenue (Q: Sep. 2018 )
	=	-0.832	/	2.394
	=	-34.75 %

Medite Cancer Diagnostics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4203 SouthWest 34th Street, Orlando, FL, USA, 32811

Website

http://www.medite-group.com

Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Executives

Lewis William Austin Iv	director, 10 percent owner	201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles	director	2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson	director	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines